This HTML5 document contains 107 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.3389/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q98226193
rdf:type
wikibase:Item
schema:description
article scientifique publié en 2020 wetenschappelijk artikel наукова стаття, опублікована 14 липня 2020 im Juli 2020 veröffentlichter wissenschaftlicher Artikel artículu científicu espublizáu en xunetu de 2020 scientific article published on 14 July 2020
p:P577
wds:Q98226193-2F567007-6814-4604-B7CF-5053B8CBE8ED
wdt:P577
2020-07-14T00:00:00Z
p:P2860
wds:Q98226193-765FF16D-8258-4103-BAD4-5A90E6A2AC43 wds:Q98226193-7A883C48-245C-4FF1-954D-B266F7E9B693 wds:Q98226193-7E7D9189-6921-40CB-9735-5E5624EE606C wds:Q98226193-817F19A1-8095-4A21-967D-16C6A80AEDBA wds:Q98226193-6C801706-710A-4256-9642-3B1E89993089 wds:Q98226193-749A2E2D-598D-4747-8EEF-40ADAE5DB0B3 wds:Q98226193-75626F71-22EA-4AD7-8D8D-C86215C17C74 wds:Q98226193-59D2BE32-C931-48F4-8A12-CE79015212A1 wds:Q98226193-5A6D837C-7123-4C66-A6BD-92BFC3729744 wds:Q98226193-63F73182-834F-4D8B-AC6A-0BB895AD78CA wds:Q98226193-48BEF6CB-5E33-4D8D-9B28-71D2A03DD070 wds:Q98226193-4B75A811-EE01-470B-BD1D-C6772C0598A6 wds:Q98226193-571F2E42-BEC6-42CE-84F1-3092727964B8 wds:Q98226193-585F516D-918D-4461-BE6F-AE08851353BE wds:Q98226193-E1511250-97E1-4F13-A640-69031B805F57 wds:Q98226193-E40A5D89-99E8-458E-A726-63C08BCEA2B5 wds:Q98226193-F880A11D-A96E-4742-8E0A-7C987AE36D44 wds:Q98226193-C9380554-83FF-46B8-8997-4ACB1F06FC16 wds:Q98226193-D0038032-FFE7-4D57-93DC-968477B5CF64 wds:Q98226193-D62031C4-EC78-46BC-9CD6-B3271BEB05E9 wds:Q98226193-AE83CEB3-37C6-4793-975C-3A1FFB59515F wds:Q98226193-BA88E14A-EAAE-487E-8B27-0B9B8CDCC3FC wds:Q98226193-84CA1456-3067-486F-9D6D-AA8A25BCB3A7 wds:Q98226193-8732EC8C-0877-4941-B390-0E29EC79F510 wds:Q98226193-AD2919DA-07CC-442D-8BE2-66881453F1FE wds:Q98226193-38933C17-ACF4-44C9-AFB3-9281D7F110CF wds:Q98226193-3CD25178-6E0B-420C-A1C4-D9086C190397 wds:Q98226193-2EF09A3F-C514-46CC-B051-24C22401DF00 wds:Q98226193-11945A44-EDD7-427B-A59F-5299519AE94C wds:Q98226193-17FAC450-E3CE-4117-834D-2328F4E9BE0E wds:Q98226193-21E1A1DA-FE56-4F92-9EA0-94B99E8367C9 wds:Q98226193-0E191E49-ECB3-4E49-8CC3-64D5C1439784
wdt:P2860
wd:Q29617472 wd:Q58294554 wd:Q71975757 wd:Q44089034 wd:Q74614286 wd:Q38000053 wd:Q35992561 wd:Q51748293 wd:Q34570396 wd:Q35756538 wd:Q35103578 wd:Q81264327 wd:Q74591878 wd:Q34657338 wd:Q37681882 wd:Q36421822 wd:Q36269807 wd:Q38939206 wd:Q47248454 wd:Q77995304 wd:Q35179811 wd:Q84488232 wd:Q34131889 wd:Q74260413 wd:Q35829609 wd:Q43980991 wd:Q73288056 wd:Q35563844 wd:Q91364306 wd:Q39884985 wd:Q38169849 wd:Q35855513
p:P2093
wds:Q98226193-427A66C1-CD02-4767-8ED8-DBF1C684E8AF wds:Q98226193-1E76311D-1334-420A-84DE-B009D5707FE3
wdt:P2093
Zin W Myint Charles A Kunos
rdfs:label
Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006-2013 Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006-2013
skos:prefLabel
Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006-2013 Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006-2013
schema:name
Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006-2013 Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006-2013
p:P1476
wds:Q98226193-D7618926-1BDD-4D16-9B0A-31828CC3A252
wdt:P1476
Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006-2013
p:P304
wds:Q98226193-71758102-41D2-486E-8D81-D6635CF38823
wdt:P304
1125
p:P31
wds:Q98226193-37783D0D-E4DC-48C5-B506-1311D8ADD547
wdt:P31
wd:Q13442814
p:P921
wds:Q98226193-FDFDC7D3-305C-4676-BB7D-56EA04628D04
wdt:P921
wd:Q68833
p:P698
wds:Q98226193-B9560332-5636-4725-9B84-85DB0D66F85A
wdtn:P698
n11:32760670
wdt:P698
32760670
p:P1433
wds:Q98226193-FD263D24-E60D-474F-8BEB-1338FD0511DF
wdt:P1433
wd:Q26839986
p:P478
wds:Q98226193-BC7DD97A-66D7-4AB0-AD14-DDDDCFE9E633
wdt:P478
10
p:P356
wds:Q98226193-302308AA-37CE-4BBA-8958-34F0D0E81607
wdtn:P356
n12:FONC.2020.01125
wdt:P356
10.3389/FONC.2020.01125
p:P275
wds:Q98226193-27e343b3-14be-4aa0-ae67-1838bc1a93e5
p:P6216
wds:Q98226193-6760053e-c828-4221-b94d-b2014c1b554f
wdt:P275
wd:Q20007257
wdt:P6216
wd:Q50423863
p:P932
wds:Q98226193-91061972-FB8F-4C5A-B92B-BF81D3211B47
wdt:P932
7372304